SCHEMBL1082579

SCHEMBL1082579

CCCCNCC1COc2c(F)cc(S(C)(=O)=O)cc2O1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.42
POLB P06746 1/20 0.41
ESR2 Q92731 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HTR6 P50406 1/20 0.36
DRD2 P14416 1/20 0.35
DRD1 P21728 1/20 0.35
DRD4 P21917 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
CA1 P00915 1/20 0.35
CA4 P22748 1/20 0.35
CA5A P35218 1/20 0.35
CA9 Q16790 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
ADRA1D P25100 4/20 0.34
ADRA1A P35348 4/20 0.34
ADRA1B P35368 4/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1082876 0.93 POLB (0.48) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1879405 0.93 POLB (0.48) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL15224266 0.92 CA2 (0.37) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1080215 0.89 CA2 (0.46) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1889166 0.89 CA2 (0.46) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1019050 0.88 CA2 (0.43) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1020197 0.87 POLB (0.41) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1882286 0.87 CA2 (0.42) CA2POLBESR2SMN1; SMN2ALDH1A1
SCHEMBL1884271 0.86 ADRA1D (0.42) CA2ALDH1A1CA1CA4CA5A
SCHEMBL1882531 0.84 HTR6 (0.50) CA2SMN1; SMN2ALDH1A1HTR6CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271634-B1 MODULATORS OF DOPAMINE NEUROTRANSMISSION INTEGRATIVE RES LAB SWEDEN AB (SE) 2014-02-12 EP claimed
US-20110105461-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2011-05-05 US claimed
EP-2271634-B1 MODULATORS OF DOPAMINE NEUROTRANSMISSION INTEGRATIVE RES LAB SWEDEN AB (SE) 2014-02-12 EP disclosed
US-8524766-B2 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2013-09-03 US disclosed
US-20110105461-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2011-05-05 US disclosed
EP-2271634-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2011-01-12 EP disclosed
WO-2009133107-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105461-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION DBH, SLC18A2, SLC6A3 CA2 3728/4885POLB 4159/4885ESR2 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.